

Plerixafor Off-Label Transplant Use
EBMT Non-Interventional Study

CENTRE REGISTRATION

STUDY

Label indication: Plerixafor is indicated in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly.

Centre eligibility criteria:

Does your centre routinely use plerixafor for non-label indications? Yes No

You must answer “Yes” to this question in order to participate in this study

CENTRE

EBMT Centre Identification Code (CIC):

Contact person :

Email address :

Does your centre want to participate in this non-interventional prospective study?

No, reason :

Yes

How many patients do you expect to include in this study per year?

Expected Start Date: (yyyy / mm / dd)

IDENTIFICATION & SIGNATURE

When participating:

I agree to include all consecutive patients who agree to participate in this study and declare that the inclusion of any patient in this study will not affect the management of this patient.

Signature

Name

Please send the completed form to the EBMT Data Office in Leiden asap by using

Fax (to e-mail system): **+49 180 500 290 623** or **+49 711 4900 8723**, or E-mail: **plerolebmt@lumc.nl**